Physician profile
Caroline Bang
NPI 1639840572
$7,762.70
in general payments reported to CMS, 2019-2025
26 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,605 · 2023: $1,998 · 2024: $1,670 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,157.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,029.05 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $846.28 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $808.16 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $655.54 | 2022-2025 | Caplyta |
| Noven Therapeutics, LLC | $465.51 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $465.17 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $436.87 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $365.16 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $362.44 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $348.15 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $321.88 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $288.37 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $245.62 | 2022-2025 | Quviviq, Quviviq |
| Neos Therapeutics, LP | $226.71 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $175.07 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $163.57 | 2022-2025 | Wellbutrin, Aplenzin |
| Vanda Pharmaceuticals INC. | $154.99 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $154.35 | 2022-2023 | Austedo Xr |
| Tris Pharma INC | $57.78 | 2025 | Dyanavel Xr, Onyda Xr |
| Tms Neurohealth Centers INC. | $43.88 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $40.23 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $27.04 | 2022 | |
| Sage Therapeutics, LLC | $25.53 | 2024 | |
| Tempus Ai, INC | $22.84 | 2024 | Tempus Pixel |
| Neurocrine Biosciences, INC. | $20.40 | 2022 | |
| Neuronetics, INC. | $12.11 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.